1. Patients in the ivonescimab group demonstrated a significantly greater progression-free survival than those in the pembrolizumab group. 2. Grade...

1. There was no significant difference in functional outcome between both groups at 96 weeks. 2. Exenatide was safe and...

1. There were no gastric and adrenal puncture instances among patients who underwent radio-ablation in both groups. 2. Majority of...

1. Progression-free survival was significantly greater in the nivolumab plus ipilimumab group compared to nivolumab alone. 2. Treatment-related adverse events...

1. 5-year breast cancer-specific survival was comparable between annual and less frequent mammography groups. 2. Less-frequent mammographic surveillance showed a...

1. Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events...

1. Composite of coronary heart disease death and non-fatal myocardial infarction was less frequent in the CCTA group compared to...

1. Progression-free survival was significantly greater in the lenvatinib plus pembrolizumab group compared to placebo. 2. Overall survival was higher...

1. Treatment failure was greater in the antibiotic group compared to appendicectomy group. 2. Significantly more patients in the antibiotic...

1. Patients in the endovascular therapy group achieved greater functional outcomes at 90 days. 2. Endovascular therapy resulted in significantly...